BridgeBio (BBIO) investor relations material

Company overview and commercial performance

• Focused on delivering meaningful medicines quickly and maintaining financial sustainability, with three approved products and a robust pipeline.

• Reported $180.6 million in Q1 U.S. revenue, annualizing to $720 million, with expectations to achieve blockbuster status globally this year.

• Attruby is projected to reach $4 billion in U.S. peak sales, with the next three pipeline products expected to add at least $4 billion in aggregate.

• Expansion indications and ongoing trials could increase de-risked peak year sales to $10 billion within two years.

Market dynamics and product differentiation

• ATTR-CM market estimated at $15–$20 billion, with current 25% share in treatment-naive patients and a target of 30–40% at peak.

• Attruby’s differentiation is driven by efficacy, safety, and convenience, with strong data on serum TTR increases and reduction in all-cause mortality.

• Real-world evidence and subgroup analyses, such as AFib and renal protection, reinforce Attruby’s clinical benefits.

• Growing combination use and frontline adoption signal increasing physician confidence.

Growth outlook and commercial strategy

• Continued share gains in the frontline setting and expanding combination use are expected to drive growth into 2Q and beyond.

• Patient assistance program’s impact on revenue is diminishing as the proportion of new starts declines.

• Physician adoption increases with exposure to new data, with a typical six to nine month lag from data generation to behavioral change.

• Real-world evidence and new clinical data are expected to further boost uptake among treatment-naive patients.